Skip to content
Could SER-109 be an Answer for Recurrent C.Difficile Infection? episode artwork

Feb 22, 2022 5 min

Could SER-109 be an Answer for Recurrent C.Difficile Infection?

from Evidence Based Medicine presented by InpharmD™

A phase 3, double-blind, randomized, placebo-controlled trial conducted to show superiority of SER-109 in reducing the risk of C. difficile infection recurrence up to 8 weeks after treatment.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Could SER-109 be an Answer for Recurrent C.Difficile Infection?

0:00 5:11

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Evidence Based Medicine presented by InpharmD™?

This episode is 5 minutes long.

When was this Evidence Based Medicine presented by InpharmD™ episode published?

This episode was published on February 22, 2022.

Can I download this Evidence Based Medicine presented by InpharmD™ episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.